Market Overview

Morgan Stanley Sees More Reasons to be Positive on Solazyme

Share:

In a report published Thursday, Morgan Stanley analyst Charles A. Dan reiterated an Overweight rating and $15.00 price target on Solazyme (NASDAQ: SZYM).

In the report, Morgan Stanley noted, “Solazyme's competitive advantages include: 1) proprietary technology that seems to be ahead of other industrial biology companies', 2) prowess in partnering with large global chemicals/nutritionals companies, 3) cost advantage producing many of the initial products it is targeting. Our base case assumes that management executes on its existing partnerships and projects. If management hits its profitability targets, we see significant upside to our forecasts. Solazyme's oils are drop-in replacements for many natural and petroleum-derived oils, and do not require additional finishing steps to be usable in current infrastructure.”

Solazyme closed on Wednesday at $11.81.

Latest Ratings for SZYM

DateFirmActionFromTo
Mar 2016MaintainsNeutral
Nov 2014DowngradesOverweightEqual-Weight
Nov 2014MaintainsNeutral

View More Analyst Ratings for SZYM
View the Latest Analyst Ratings

Posted-In: Charles A. Dan Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (SZYM)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
DEReiterates175.0
AMWDMaintains92.0
FTDRMaintains55.0
REDUDowngrades
ZSDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Clean Harbors Downgraded by Wedbush After Disappointing Q4 Results

Morgan Stanley is Still Waiting for Signs of Turnaround from J.C. Penney